Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

276 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Characteristics and outcomes of patients with acute promyelocytic leukemia and extreme hyperleukocytosis at presentation.
Iland HJ, Russell N, Dillon R, Schuh AC, Tedjaseputra A, Wei A, Khwaja A, Knapper S, Lane SW, Reynolds J, McMullin MF, Martin A, Tan P, Taussig DC, Wong A, Taper J, Fraga C, Kelly R, Tawana K, Mehta P, Mina A, Altman JK, Mølle I, Tauro S, Tholouli E. Iland HJ, et al. Among authors: mcmullin mf. Blood Adv. 2023 Jun 13;7(11):2580-2585. doi: 10.1182/bloodadvances.2022007126. Blood Adv. 2023. PMID: 36075018 Free PMC article. No abstract available.
The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison.
Burnett AK, Hills RK, Hunter AE, Milligan D, Kell WJ, Wheatley K, Yin J, McMullin MF, Dignum H, Bowen D, Russell NH; UK National Cancer Research Institute AML Working Group. Burnett AK, et al. Among authors: mcmullin mf. Leukemia. 2013 Jan;27(1):75-81. doi: 10.1038/leu.2012.229. Epub 2012 Aug 14. Leukemia. 2013. PMID: 22964882 Clinical Trial.
Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial.
Burnett AK, Russell NH, Hills RK, Bowen D, Kell J, Knapper S, Morgan YG, Lok J, Grech A, Jones G, Khwaja A, Friis L, McMullin MF, Hunter A, Clark RE, Grimwade D; UK National Cancer Research Institute Acute Myeloid Leukaemia Working Group. Burnett AK, et al. Among authors: mcmullin mf. Lancet Oncol. 2015 Oct;16(13):1295-305. doi: 10.1016/S1470-2045(15)00193-X. Epub 2015 Sep 14. Lancet Oncol. 2015. PMID: 26384238 Clinical Trial.
Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide.
Harrison CN, Mead AJ, Panchal A, Fox S, Yap C, Gbandi E, Houlton A, Alimam S, Ewing J, Wood M, Chen F, Coppell J, Panoskaltsis N, Knapper S, Ali S, Hamblin A, Scherber R, Dueck AC, Cross NCP, Mesa R, McMullin MF. Harrison CN, et al. Among authors: mcmullin mf. Blood. 2017 Oct 26;130(17):1889-1897. doi: 10.1182/blood-2017-05-785790. Epub 2017 Aug 9. Blood. 2017. PMID: 29074595 Free PMC article. Clinical Trial.
Defining the Optimal Total Number of Chemotherapy Courses in Younger Patients With Acute Myeloid Leukemia: A Comparison of Three Versus Four Courses.
Burnett AK, Russell NH, Hills RK, Knapper S, Freeman S, Huntly B, Clark RE, Thomas IF, Kjeldsen L, McMullin MF, Drummond M, Kell J, Spearing R. Burnett AK, et al. Among authors: mcmullin mf. J Clin Oncol. 2021 Mar 10;39(8):890-901. doi: 10.1200/JCO.20.01170. Epub 2020 Dec 23. J Clin Oncol. 2021. PMID: 33356418 Free PMC article. Clinical Trial.
Guideline for the diagnosis and management of myelofibrosis.
Reilly JT, McMullin MF, Beer PA, Butt N, Conneally E, Duncombe A, Green AR, Michaeel NG, Gilleece MH, Hall GW, Knapper S, Mead A, Mesa RA, Sekhar M, Wilkins B, Harrison CN; Writing group: British Committee for Standards in Haematology. Reilly JT, et al. Among authors: mcmullin mf. Br J Haematol. 2012 Aug;158(4):453-71. doi: 10.1111/j.1365-2141.2012.09179.x. Epub 2012 Jun 1. Br J Haematol. 2012. PMID: 22651893 Free article.
Inclusion of chemotherapy in addition to anthracycline in the treatment of acute promyelocytic leukaemia does not improve outcomes: results of the MRC AML15 trial.
Burnett AK, Hills RK, Grimwade D, Jovanovic JV, Craig J, McMullin MF, Kell J, Wheatley K, Yin JA, Hunter A, Milligan D, Russell NH; United Kingdom National Cancer Research Institute Acute Myeloid Leukaemia Subgroup. Burnett AK, et al. Among authors: mcmullin mf. Leukemia. 2013 Apr;27(4):843-51. doi: 10.1038/leu.2012.360. Epub 2012 Dec 10. Leukemia. 2013. PMID: 23222369 Clinical Trial.
Use of JAK inhibitors in the management of myelofibrosis: a revision of the British Committee for Standards in Haematology Guidelines for Investigation and Management of Myelofibrosis 2012.
Reilly JT, McMullin MF, Beer PA, Butt N, Conneally E, Duncombe AS, Green AR, Mikhaeel G, Gilleece MH, Knapper S, Mead AJ, Mesa RA, Sekhar M, Harrison CN. Reilly JT, et al. Among authors: mcmullin mf. Br J Haematol. 2014 Nov;167(3):418-20. doi: 10.1111/bjh.12985. Epub 2014 Jun 25. Br J Haematol. 2014. PMID: 24961987 Free article. No abstract available.
276 results